NCT06295458Completed
Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait
Source: ClinicalTrials.gov · Last updated 4 Aug 2026
Brief summary (registry, in English)
This study aims to answer the question: to assess the safety, and tolerability of gamma light in Parkinson's disease (PD) patients with freezing of gait (FOG). Parkinson's disease (PD) patients often experience a complex gait disorder known as Freezing of Gait (FOG). FOG is characterized by brief arrests of stepping when initiating gait, turning, and walking straight and patients describe it as their feet being "glued" to the floor. FOG in Parkinson's disease (PD) is a considerable public health burden worldwide. It is a poorly understood gait symptom that has potentially grave consequences as FOG is intermittent and unpredictable, a leading cause of falls with injury, and results in loss of independence. FOG is generally found to be associated with cognitive decline, particularly executive dysfunction which, in turn, has been associated with higher spinal fluid amyloid (Aβ42) levels in PD. There is data linking amyloid to FOG. A previous study showed that the gamma light helped reduce some amyloid. The research team is studying if gamma light exposure for 1 hour daily is well tolerated. Also, does it have any effect on freezing of gait severity?
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 22 Jan 2024
- Start date
- 8 Jul 2024
- Primary completion date
- 4 May 2026
- Lead sponsor
- Emory University
- Diseases
- Parkinson disease
- NCT number
- NCT06295458
What you commit to
- Study type: Interventional
- Participants enrolled: 24
- From 8 Jul 2024 to the primary completion date, 4 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with medications that cause Parkinsonism
Other illness
- Neurological or orthopedic disorders interfering with gait
- Dementia precluding completing the study protocol, including those meeting criteria for dementia with Lewy bodies
- Major depression based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria
- Any medical problems that would preclude participation, including individuals with a history of migraines, tinnitus, or seizures, because sensory stimuli can potentially exacerbate these conditions.
Other
- A diagnosis of atypical Parkinsonism, including vascular Parkinsonism
- Stage V PD -unable to walk independently when OFF
- Absence of levodopa response
- Profound sensory loss as determined by the investigator.
Who the study is looking for
- PD Diagnosis by UK Brain Bank Criteria
- Hoehn \& Yahr stage I-IV in the off-state
- FOG noted in medical history
- FOG confirmed visually by the examiner in the office
- PD that is levodopa-treated and responsive
- Able to manage 12 hours of "OFF" dopaminergic medication state
- Age 50-80 years
- Able to sign a consent document and willing to participate in all aspects of the study
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory Movement Disorders Center Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.